Company intelligence / Profile preview

Cellinta

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Cellinta is developing first-in-class, highly selective gene therapies that use viral vectors and master regulators of cell identity to deliver therapeutic payloads specifically to cancer stem cells; programs are currently in preclinical development with no disclosed clinical trial results yet.[1][2]

Therapeutic areas: Oncology
Modalities: Gene therapyViral vector-based therapy
Industry: Biotech

Partnerships

Cancer Research UK[1][2]University of Edinburgh[1][2]

Beyond the preview

Go deeper on Cellinta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellinta.

Explore the full profile